Cancer Immunotherapy
- 1st Edition, Volume 164 - August 4, 2019
- Latest edition
- Editor: David B. Teplow
- Language: English
Cancer Immunotherapy, Volume 165 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related t… Read more
Cancer Immunotherapy, Volume 165 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to different approaches to cancer immunotherapy, with this release focusing on TNFR2 in cancer immunology and immunotherapy, From the Hellstrom paradox towards cancer cure, CAR T-cell treatment of T-cell malignancy , Immunotherapy of pancreatic cancer, Cancer stem cell immunology/immunotherapy,
Cytokine release syndrome, Tumor cell-based mechanisms of resistance to immune attack, and Mushroom compounds in cancer immunotherapy.
- Includes comprehensive coverage of molecular biology
- Presents ample use of tables, diagrams, schemata and color figures to enhance the reader's ability to rapidly grasp the information provided
- Contains contributions from renowned experts in the field
Progress in Molecular Biology and Translational Science will be useful for scientists working actively in a field, including those at levels ranging from graduate student to senior investigator. Volumes also are appropriate for new investigators to a field who wish to familiarize themselves with the latest work
1. TNFR2 in cancer immunology and immunotherapy
Xin Chen
2. From the Hellstrom paradox towards cancer cure
Ingegerd Hellstrom and Karl Erik Hellstrom
3. CAR T-cell treatment of T-cell malignancy
Martin Pule
4. Immunotherapy of pancreatic cancer
Jorg Kleeff
5. Cancer stem cell immunology/immunotherapy
Federica Cavallo
6. Cytokine release syndrome
Alexander Shimabukuro-Vornhagen
7. Tumor Cell-Based Mechanisms of Resistance to Immune Attack
Louis M. Weiner
8. Mushroom compounds in cancer immunotherapy
Peter Amwoga Ayeka
- Edition: 1
- Latest edition
- Volume: 164
- Published: August 4, 2019
- Language: English
DT
David B. Teplow
David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Co-Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.
Affiliations and expertise
Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USARead Cancer Immunotherapy on ScienceDirect